Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC

February 20, 2026 | Joel Neal, MD, PhD, and Sarah B. Goldberg, MD, MPH

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, review the evolving frontline treatment landscape for EGFR-mutated advanced NSCLC. The pair discussed how combination regimens have come to the forefront of first-line treatment in EGFR-mutated NSCLC, with osimertinib plus chemotherapy and amivantamab plus lazertinib both demonstrating improved outcomes vs osimertinib monotherapy in the space. Neal and Goldberg detailed how they weigh combination vs monotherapy approaches in current practice and other factors that drive first-line care.